Kiefer Greenspan
Psychiatry · Orange, CANPI 1629573464
Payments from drug & device makers
Across 555 payments — averaging $24.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$1K
- Neuronetics, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Axsome Therapeutics, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Lundbeck LLC$1K
- plus $7K from 25 others
What the payments were for
- Travel & lodging$7385%
- Food & beverage$12,89394%
- Education$560%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 48 | $1,447 |
| Neuronetics, Inc. | 3 | $1,292 |
| Teva Pharmaceuticals USA, Inc. | 73 | $1,239 |
| Axsome Therapeutics, Inc. | 43 | $1,059 |
| Neurocrine Biosciences, Inc. | 40 | $1,008 |
| Lundbeck LLC | 53 | $1,006 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $972 |
| Johnson & Johnson | 35 | $958 |
| Otsuka America Pharmaceutical, Inc. | 40 | $844 |
| Alkermes, Inc. | 34 | $669 |
| Bausch Health US, LLC | 25 | $478 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $421 |
| E.r. Squibb & Sons, L.L.C. | 13 | $384 |
| Ironshore Pharmaceuticals Inc. | 16 | $347 |
| Sunovion Pharmaceuticals Inc. | 9 | $256 |
| AbbVie | 10 | $219 |
| Indivior Inc. | 7 | $193 |
| Corium, LLC | 10 | $186 |
| Biogen | 9 | $172 |
| Noven Therapeutics, LLC | 7 | $128 |
| Vertical Pharmaceuticals, LLC | 4 | $87 |
| Tempus AI, Inc | 2 | $51 |
| OWP Pharmaceuticals, Inc. | 2 | $49 |
| Tris Pharma Inc | 2 | $42 |
| Pfizer | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Almatica Pharma LLC | 1 | $26 |
| Braeburn Inc. | 1 | $26 |
| Masimo Corporation | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Neos Therapeutics, LP | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$1,275
- Auvelity$125
- Fanapt$125
How this compares
$13,686 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 20 | $30,203 |
| CaplytaLumateperone Tosylate | 13 | $20,818 |
| Lisdexamfetamine Dimesylate | 14 | $3,481 |
| Aripiprazole | 60 | $2,365 |
| Bupropion XlBupropion Hcl | 96 | $2,202 |
| Divalproex Sodium ErDivalproex Sodium | 24 | $1,889 |
| Quetiapine Fumarate | 69 | $1,567 |
| Olanzapine | 51 | $1,521 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 33 | $1,459 |
| Gabapentin | 61 | $928 |
| Ramelteon | 11 | $893 |
| Trazodone Hcl | 97 | $874 |
| Duloxetine Hcl | 46 | $704 |
| Mirtazapine | 44 | $659 |
| Escitalopram Oxalate | 89 | $646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $844 | $30,20320 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $972 | $20,81813 claims |
| Almatica Pharma LLCSertraline Hcl | $26 | $30582 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Orange
- Daniel ChuehOrange$17.9M
- Gustavo AlvaOrange$9.8M
- Elly LeeIrvine$49.8M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.